Table 1.
Baseline Characteristics of the ASPIRE-VA Participants in Initial and Follow-Up Treatment
| Characteristics | Total (n = 481) | Follow-up Yes (n = 332) | Follow-up No (n = 149) | p values |
|---|---|---|---|---|
| Age, M (SD) | 55.0 (10.0) | 55.98 (9.5) | 52.69 (10.7) | <0.001 |
| BMI (kg/m2) | 36.5 (6.2) | 36.2 (6.0) | 37.1 (6.7) | 0.12 |
| Male | 409 (85.0) | 284 (85.5) | 125 (83.9) | 0.64 |
| Race/ethnicity | ||||
| Black | 196 (40.7) | 135 (40.7) | 61 (40.9) | |
| White | 276 (57.4) | 194 (58.43) | 82 (55.03) | 0.06 |
| Other | 9 (1.9) | 3 (0.90) | 6 (4.027) | |
| Education, years | ||||
| < 13 | 108 (22.5) | 73 (22.0) | 35 (23.5) | |
| 13–16 | 254 (52.8) | 174 (52.4) | 80 (53.7) | 0.46 |
| ≥ 16 | 108 (22.5) | 75 (22.6) | 33 (22.2) | |
| Missing | 11 (2.3) | 10 (3.0) | 1 (0.7) | |
| Income < $20,000 | 196 (42.9) | 137 (43.9) | 59 (40.7) | 0.52 |
| Health-related disability | 249 (55.2) | 166 (54.1) | 83 (57.6) | 0.48 |
| Charlson Comorbidity Index, M (SD) | 1.1 (1.5) | 1.2 (1.5) | 0.98 (1.4) | 0.16 |
| Depression | 156 (32.5) | 105 (31.7) | 51 (34.2) | 0.59 |
| PTSD | 76 (15.8) | 57 (17.2) | 19 (12.8) | 0.22 |
| Serious mental illness | 31 (6.5) | 18 (5.4) | 13 (8.7) | 0.18 |
| Substance use disorder | 82 (17.0) | 57 (17.17) | 25 (16.78) | 0.90 |
| Diabetes | 177 (36.8) | 122 (36.8) | 55 (36.9) | 0.97 |
| Hypertension | 319 (66.3) | 226 (68.1) | 93 (62.4) | 0.23 |
| Hypercholesterolemia | 244 (50.8) | 171 (51.51) | 73 (48.99) | 0.61 |
| EQ-5D pain | ||||
| None | 89 (18.8) | 64 (19.6) | 25 (17.0) | |
| Moderate | 323 (68.3) | 218 (66.9) | 105 (71.4) | 0.62 |
| Severe | 61 (12.9) | 44 (13. 5) | 17 (11. 6) | |
| Site | ||||
| Site 1 | 239 (49.7) | 167 (50.3) | 72 (48.3) | 0.69 |
| Site 2 | 242 (50.3) | 165 (49.7) | 77 (51.7) | |